Results 231 to 240 of about 1,939,761 (391)

a-Logic With Arrows

open access: diamond, 2008
Murdoch J. Gabbay, Michael J. Gabbay
openalex   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

open access: yesMolecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj   +4 more
wiley   +1 more source

Interactions Between Tryptase-Positive Mast Cells and Melanin-A<sup>+</sup> Cells in the Microenvironment of Cutaneous Melanoma. [PDF]

open access: yesInt J Mol Sci
Atiakshin D   +16 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

Pulmonary interstitial emphysema: A rare complication in adults (Report of two cases). [PDF]

open access: yesRadiol Case Rep
Ayez M   +9 more
europepmc   +1 more source

Approval voting and Arrow’s impossibility theorem

open access: yesSocial Choice and Welfare, 2015
François Maniquet, P. Mongin
semanticscholar   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy